Gene Therapies For Rare Diseases Market
完整報告名稱與涵蓋範圍
Gene Therapies For Rare Diseases Market Size, Share & Trends Analysis Report By Product (Zolgensma, Invossa K, Strimvelis, Neovasculgen, Glybera, Luxturna, Zynteglo, and Others), By Disease Type, Region And Segment Forecasts, 2023-2031.
報告摘要
A CAGR of 20.0% is forecasted for the global Gene Therapies For Rare Diseases Market over the assessment period of 2023 through 2031.
Gene Therapies For Rare Diseases covers disease management. Rapid advancements and evolving end-user preferences are reshaping how healthcare entities approach this space.
Growth is driven by a convergence of factors: rising awareness among end users, continuous product innovation, and the mounting emphasis on efficiency and sustainability within the healthcare sector.
Segmental analysis reveals differentiated growth across product categories, applications, and geographical regions, with certain niches demonstrating above-average expansion potential.
From a regional perspective, mature markets in North America and Europe continue to hold pronounced shares, while the Asia-Pacific region is gaining momentum through accelerated economic development and mounting investment in the sector.
Competition in this space is characterized by active product development, strategic collaborations, and geographic expansion among both global leaders and specialized niche players.
This comprehensive research study delivers granular insights into market sizing, trend analysis, competitive benchmarking, and forward-looking projections to support strategic decision-making for industry participants and investors.
授權報價
| Single User PDF | $4,500 USD |
| Global Site License PDF | $9,500 USD |
目錄 Table of Contents
Chapter 1. Methodology and Scope
1.1. Research Methodology
1.2. Research Scope & Assumptions
Chapter 2. Executive Summary
Chapter 3. Global Gene Therapies for Rare Diseases Market Snapshot
Chapter 4. Global Gene Therapies for Rare Diseases Market Variables, Trends & Scope
4.1. Market Segmentation & Scope
4.2. Drivers
4.3. Challenges
4.4. Trends
4.5. Penetration & Growth Prospect Mapping
4.6. Clinical Trial/Pipeline Analysis
4.7. Industry Analysis – Porter's Five Forces Analysis
4.8. Competitive Landscape & Market Share Analysis
4.9. Technology Advancement in Gene Therapies for Rare Diseases Market
Chapter 5. Market Segmentation 1: Product Estimates & Trend Analysis
5.1. Product Type & Market Share, 2020 & 2028
5.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2020 to 2028 for the following Product:
5.2.1. Zolgensma
5.2.2. Invossa K
5.2.3. Strimvelis
5.2.4. Neovasculgen
5.2.5. Glybera
5.2.6. Luxturna
5.2.7. Zynteglo
5.2.8. Others
Chapter 6. Gene Therapies for Rare Diseases Market Segmentation 2: Application Estimates & Trend Analysis
6.1. Disease Type Analysis & Market Share, 2020 & 2028
6.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2020 to 2028 for the following Disease Type:
6.2.1. Human Medicine
6.2.2. Human Medicine
6.2.3. Hemophilia
6.2.4. Duchenne Muscular Dystrophy
6.2.5. Achromatopsia
6.2.6. Cystic Fibrosis
6.2.7. Inherited Retinal Dystrophy
6.2.8. Fragile X Syndrome
6.2.9. Friedreich ataxia
6.2.10. Alpha-1 Antitrypsin Deficiency
6.2.11. Paroxysmal Nocturnal Hemoglobinuria
6.2.12. Retinitis Pigmentosa
6.2.13. Others
Chapter 7. Gene Therapies for Rare Diseases Market Segmentation 3: Regional Estimates & Trend Analysis
7.1. North America
7.1.1. North America Gene Therapies for Rare Diseases Market revenue (US$ Million) estimates and forecasts by product, 2020-2028
7.1.2. North America Gene Therapies for Rare Diseases Market revenue (US$ Million) estimates and forecasts by Disease Type, 2020-2028
7.1.3. North America Gene Therapies for Rare Diseases Market revenue (US$ Million) estimates and forecasts by country, 2020-2028
7.1.3.1. U.S.
7.1.3.2. Canada
7.2. Europe
7.2.1. Europe Gene Therapies for Rare Diseases Market revenue (US$ Million) by product, 2020-2028
7.2.2. Europe Gene Therapies for Rare Diseases Market revenue (US$ Million) by Disease Type, 2020-2028
7.2.3. Europe Gene Therapies for Rare Diseases Market revenue (US$ Million) by country, 2020-2028
7.2.3.1. Germany
7.2.3.2. Poland
7.2.3.3. France
7.2.3.4. Italy
7.2.3.5. Spain
7.2.3.6. UK
7.2.3.7. Rest of Europe
7.3. Asia Pacific
7.3.1. Asia Pacific Gene Therapies for Rare Diseases Market revenue (US$ Million) by product, 2020-2028
7.3.2. Asia Pacific Gene Therapies for Rare Diseases Market revenue (US$ Million) by Disease Type, 2020-2028
7.3.3. Asia Pacific Gene Therapies for Rare Diseases Market revenue (US$ Million) by country, 2020-2028
7.3.3.1. China
7.3.3.2. India
7.3.3.3. Japan
7.3.3.4. Australia
7.3.3.5. Rest of Asia Pacific
7.4. Latin America
7.4.1. Latin America Gene Therapies for Rare Diseases Market revenue (US$ Million) by product, (US$ Million)
7.4.2. Latin America Gene Therapies for Rare Diseases Market revenue (US$ Million) by Disease Type, (US$ Million)
7.4.3. Latin America Gene Therapies for Rare Diseases Market revenue (US$ Million) by country, (US$ Million) 2020-2028
7.4.3.1. Brazil
7.4.3.2. Rest of Latin America
7.5. MEA
7.5.1. MEA revenue Gene Therapies for Rare Diseases Market revenue (US$ Million) by product, (US$ Million) 2020-2028
7.5.2. MEA Gene Therapies for Rare Diseases Market revenue (US$ Million) by Disease Type, (US$ Million)
7.5.3. MEA Gene Therapies for Rare Diseases Market revenue (US$ Million) by country, (US$ Million) 2020-2028
Chapter 8. Competitive Landscape
8.1. Company Profiles
8.1.1. 4d Molecular Therapeutics, LLC
8.1.2. Abeona Therapeutics Inc.
8.1.3. Advaxis
8.1.4. Adverum Biotech
8.1.5. Aevi Genomic
8.1.6. Applied Genetic Technologies Corporation (AGTC)
8.1.7. Alcyone Lifesciences
8.1.8. Allife Medical Science and Technology
8.1.9. Amarna Therapeutics
8.1.10. American Gene Technologies
8.1.11. Amgen
8.1.12. Amicus Therapeutics
8.1.13. Anchiano Therapeutics
8.1.14. AnGes MG
8.1.15. Apic Bio
8.1.16. Armata Pharmaceuticals
8.1.17. Arrowhead
8.1.18. Arthrogen
8.1.19. Asklepios
8.1.20. Astellas
8.1.21. AVROBIO
8.1.22. BCM Families Foundation
8.1.23. Beijing Northland
8.1.24. Benitec
8.1.25. Biogen
8.1.26. BioMarin
8.1.27. Biosidus
8.1.28. bluebird bio
8.1.29. Boryung Group
8.1.30. Brain Neurotherapeuticsy Bio
8.1.31. Celsion Corporation
8.1.32. Chiesi
8.1.33. CRISPR Therapeutics
8.1.34. CSL Behring
8.1.35. Daewoong Pharma
8.1.36. Dicerna
8.1.37. Editas Medicine
8.1.38. Eiger BioPharmaceuticals
8.1.39. Enzo Therapeutics
8.1.40. Esteve
8.1.41. Evox Therapeutics
8.1.42. Expression Therapeutics
8.1.43. Fibrocell
8.1.44. Flexion Therapeutics,
8.1.45. Fortress Biotech
8.1.46. Freeline Therapeutics
8.1.47. Gene Biotherapeutics
8.1.48. Genenta Science
8.1.49. GeneQuine
8.1.50. Genethon
8.1.51. GenSight
8.1.52. Gilead
8.1.53. Gradalis
8.1.54. GSK
8.1.55. Hanugen
8.1.56. Helixmith
8.1.57. Herantis
8.1.58. ID Pharma
8.1.59. Immusoft
8.1.60. Inovio
8.1.61. Intellia Therapeutics
8.1.62. Intrexon
8.1.63. Juventas
8.1.64. Kolon Life Science
8.1.65. Krystal Biotech
8.1.66. Locana
8.1.67. LogicBio Therapeutics
8.1.68. Lysogene
8.1.69. Medigene
8.1.70. MeiraGTx
8.1.71. Miltenyi Biotec
8.1.72. Molecular Templates
8.1.73. Momotaro-Gene
8.1.74. Neuralgene
8.1.75. Novartis
8.1.76. OncoSec
8.1.77. Orchard Therapeutics
8.1.78. Oxford Biomedica
8.1.79. Pfizer
8.1.80. Prevail Therapeutics
8.1.81. PTC Therapeutics
8.1.82. REGENXBIO
8.1.83. Renova Therapeutics
8.1.84. Reyon Pharmaceutical
8.1.85. Roche
8.1.86. Rocket Pharma
8.1.87. Roivant
8.1.88. Sangamo Therapeutics
8.1.89. Sarepta Therapeutics
8.1.90. Seelos Therapeutics
8.1.91. Solid BioSciences
8.1.92. Sterna Biologicals
8.1.93. Sutura Therapeutics
8.1.94. SynerGene
8.1.95. Takara
8.1.96. Takeda
8.1.97. Talee Bio
8.1.98. Theragene Pharma
8.1.99. Transgene
8.1.100. Ultragenyx
8.1.101. uniQure
8.1.102. VBL Therapeutics
8.1.103. Vertex
8.1.104. Voyager Therapeutics
8.1.105. Xalud
8.1.106. Xenon
8.1.107. Ziopharm
常見問題
這份報告可以先索取樣本嗎？
可以。建議購買前先申請樣本，提出申請後約 2 個工作天內提供，您可以先確認內容涵蓋範圍是否符合需求。
報告價格如何計算？
報告以美元標價，台幣報價依當日匯率換算並加計 5% 營業稅。不同授權版本（單人／多人／企業全站）價格不同，量子訊息會評估您的使用情境後提供最優惠報價。
下單後多久交付？如何付款？
一般 3–7 個工作天交付，實際依出版商狀況於下單前確認。收到報告確認無誤後開立台幣發票，30 天內電匯付款即可。
量子訊息有限公司為 InsightAce Analytic 在台灣的授權代理，提供報告購買、樣本申請與授權諮詢。電話 +886 2 7751 5192 ・ 聯絡我們